By Denny Jacob
Salarius Pharmaceuticals has agreed to merge with biopharmaceutical company Decoy Therapeutics.
The companies said Monday that the agreement, unanimously approved by both companies' boards, will leave Decoy investors with about 86% ownership of the outstanding shares of the combined company. Salarius shareholders would own about 14% of the outstanding shares.
The proposed deal is expected to create opportunities within Decoy's pipeline of peptide conjugate therapeutics, among other efforts.
The newly formed company will be led by Decoy co-founders, Chief Executive Frederick Pierce and Chief Scientific Officer Barbara Hibner, and Salarius' Chief Financial Officer Mark Rosenblum, among others.
The combined company will retain the Decoy name. Its board will consist of Pierce, Hibner and three independent directors, two being appointed by Decoy's board and one by Salarius' board.
Shares of Salarius more than doubled to $3.53 in premarket trading Monday.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
January 13, 2025 08:48 ET (13:48 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。